Adrenocortical Carcinoma Treatment Market (2026 - 2035)

ID: MRFR/Pharma/5105-HCR 100 Pages Rahul Gotadki Last Updated: November 16, 2026
Adrenocortical Carcinoma Treatment Market Research Report By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa), By Country (US, Canada, Mexico, Germany, UK, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, Saudi Arabia, UAE, South Africa, Egypt), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research and Academic Institutions, Home Healthcare Settings) – Growth Outlook & Industry Forecast 2025 to 2035
Adrenocortical Carcinoma Treatment Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)6.1%
2025 Market SizeUSD 687.4 Million
2035 Market SizeUSD 1,238.0 Million
Key Players
ESTEVE
Pfizer Inc.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb
Hikma Pharmaceuticals PLC
Opportunities
  • Label-Enabling Combination Trials
  • Emerging-Market Referral Networks
  • Drug-Level Monitoring and Registry Data Services
  1. 1 Market Summary | |
  2. 2 Key Report Takeaways | |
    1. 2.1 By End User | |
    2. 2.2 By Treatment Type | |
    3. 2.3 By Disease Stage | |
    4. 2.2 By Region | |
  3. 3 Market Size and Forecast (2021–2035) | |
    1. 3.1 Historical Market Size (2021–2025) | |
    2. 3.2 Forecast Market Size (2026–2035) | |
    3. 3.3 Year-over-Year Growth Analysis | |
  4. 4 Driver Impact Analysis | |
    1. 4.1 Clinical Validation of VEGFR Inhibitor and Checkpoint Combinations | |
    2. 4.2 Rising Detection of Adrenal Masses Through Imaging | |
    3. 4.3 Orphan Drug Incentives | |
    4. 4.4 Expansion of Cooperative-Group Trial Networks | |
    5. 4.5 Guideline-Standardized EDP-M and Mitotane Monitoring | |
    6. 4.6 Oncology Capacity Build-Out in China and India | |
    7. 4.7 Specialty Pharma Investment in Rare Endocrine Portfolios | |
  5. 5 Restraints Impact Analysis | |
    1. 5.1 Very Low Disease Incidence | |
    2. 5.2 Mitotane Toxicity and Narrow Therapeutic Range | |
    3. 5.3 Modest Efficacy of Checkpoint Monotherapy | |
    4. 5.4 Lack of Newly Approved Agents | |
    5. 5.5 Expertise Concentrated in Few Referral Centers | |
  6. 6 Opportunities | |
    1. 6.1 Label-Enabling Combination Trials | |
    2. 6.2 Emerging-Market Referral Networks | |
    3. 6.3 Drug-Level Monitoring and Registry Data Services | |
    4. 6.4 Risk-Adapted Adjuvant Care | |
    5. 6.5 Maintenance Immunotherapy | |
  7. 7 Regional Market Share and Country-Level Analysis | |
    1. 7.1 North America | | |
      1. 7.1.1 US | | |
      2. 7.1.2 Canada | | |
      3. 7.1.3 Mexico | |
    2. 7.2 Europe | | |
      1. 7.2.1 Germany | | |
      2. 7.2.2 UK | | |
      3. 7.2.3 France | | |
      4. 7.2.4 Italy | | |
      5. 7.2.5 Spain | | |
      6. 7.2.6 Nordic Countries | | |
      7. 7.2.7 Russia | | |
      8. 7.2.8 Rest of Europe | |
    3. 7.3 Asia-Pacific | | |
      1. 7.3.1 China | | |
      2. 7.3.2 India | | |
      3. 7.3.3 Japan | | |
      4. 7.3.4 South Korea | | |
      5. 7.3.5 ASEAN | | |
      6. 7.3.6 Rest of Asia-Pacific | |
    4. 7.4 South America | | |
      1. 7.4.1 Brazil | | |
      2. 7.4.2 Argentina | | |
      3. 7.4.3 Rest of South America | |
    5. 7.5 Middle East & Africa | | |
      1. 7.5.1 Saudi Arabia | | |
      2. 7.5.2 UAE | | |
      3. 7.5.3 South Africa | | |
      4. 7.5.4 Egypt | | |
      5. 7.5.5 Rest of MEA | |
  8. 8 Future Outlook (2026–2035) | |
    1. 8.1 Combination Regimens Become the Second-Line Standard | |
    2. 8.2 Molecular Risk Stratification Shapes Adjuvant Spending | |
    3. 8.3 Care Moves Toward Specialty and Home Settings | |
    4. 8.4 Real-World Evidence Fills the Data Gap | |
  9. 9 Segmentation Analysis | |
    1. 9.1 By End User | | |
      1. 9.1.1 Hospitals | | |
      2. 9.1.2 Specialty Clinics | | |
      3. 9.1.3 Ambulatory Surgical Centers | | |
      4. 9.1.4 Research and Academic Institutions | | |
      5. 9.1.5 Home Healthcare Settings | |
    2. 9.2 By Treatment Type | | |
      1. 9.2.1 Surgery | | |
      2. 9.2.2 Chemotherapy | | |
      3. 9.2.3 Targeted Therapy | | |
      4. 9.2.4 Radiation Therapy | | |
      5. 9.2.5 Immunotherapy | |
    3. 9.3 By Disease Stage | | |
      1. 9.3.1 Localized Stage | | |
      2. 9.3.2 Locally Advanced Stage | | |
      3. 9.3.3 Metastatic Stage | |
  10. 10 Competitive Landscape | |
    1. 10.1 Market Concentration Analysis | |
    2. 10.2 Competitive Benchmarking Matrix | |
    3. 10.3 Company Profiles | | |
      1. 10.3.1 ESTEVE (HRA Pharma Rare Diseases) | | |
      2. 10.3.2 Pfizer Inc. | | |
      3. 10.3.3 Merck & Co., Inc. | | |
      4. 10.3.4 Teva Pharmaceutical Industries Ltd. | | |
      5. 10.3.5 Bristol Myers Squibb | | |
      6. 10.3.6 Hikma Pharmaceuticals PLC | | |
      7. 10.3.7 Exelixis, Inc. | | |
      8. 10.3.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd. | | |
      9. 10.3.9 F. Hoffmann-La Roche Ltd. | | |
      10. 10.3.10 Regeneron Pharmaceuticals, Inc. | |
  11. 11 Recent News & Developments | |
  12. 12 Report Scope and Methodology | |
  13. 13 Detailed Sources and Citations | |
  14. 14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
  15. TABLE 1 Global Market Snapshot, 2025–2035 | |
  16. TABLE 2 Global Market Size and Forecast, by Revenue (USD Million), 2021–2035 | |
  17. TABLE 3 Driver Impact Analysis, 2026–2035 | |
  18. TABLE 4 Restraints Impact Analysis, 2026–2035 | |
  19. TABLE 5 Regional Summary, 2025 | |
  20. TABLE 6 North America Market, by Country, 2025 | |
  21. TABLE 7 Europe Market, by Country, 2025 | |
  22. TABLE 8 Asia-Pacific Market, by Country, 2025 | |
  23. TABLE 9 South America Market, by Country, 2025 | |
  24. TABLE 10 Middle East & Africa Market, by Country, 2025 | |
  25. TABLE 11 Global Market, by End User, 2025 | |
  26. TABLE 12 Competitive Benchmarking Matrix, 2025 | |
  27. TABLE 13 Report Scope and Methodology | |
  28. TABLE 14 Detailed Sources and Citations | | LIST OF FIGURES | |
  29. FIGURE 1 Market Dynamics Overview (Drivers, Restraints, Opportunities) | |
  30. FIGURE 2 Industry Value Chain Analysis | |
  31. FIGURE 3 Porter's Five Forces Analysis | |
  32. FIGURE 4 Global Market Size Trend (USD Million), 2021–2035 | |
  33. FIGURE 5 Global Market Share, by End User, 2025 | |
  34. FIGURE 6 Global Market Share, by Region, 2025 | |
  35. FIGURE 7 North America Market Share, by Country, 2025 | |
  36. FIGURE 8 Europe Market Share, by Country, 2025 | |
  37. FIGURE 9 Asia-Pacific Market Share, by Country, 2025 | |
  38. FIGURE 10 South America Market Share, by Country, 2025 | |
  39. FIGURE 11 Middle East & Africa Market Share, by Country, 2025 | |
  40. FIGURE 12 Competitive Landscape Positioning Map, 2025

Segmentation Quick Reference

DimensionSub-SegmentsDominant SegmentFastest Growing Segment
By End UserHospitals; Specialty Clinics; Ambulatory Surgical Centers; Research and Academic Institutions; Home Healthcare SettingsHospitals (55.1% share)Specialty Clinics (8.4% CAGR)
By RegionNorth America; Europe; Asia-Pacific; South America; Middle East & AfricaNorth America (41.2% share)Asia-Pacific (7.8% CAGR)

Market Segmentation Overview

By End User

Sub-SegmentKey Trend
HospitalsRetain surgery, cortisol control and mitotane level testing under one roof
Specialty ClinicsAbsorb long-term follow-up and oral therapy titration for stable patients
Ambulatory Surgical CentersLimited to laparoscopic resection of small, non-invasive tumors
Research and Academic InstitutionsHost most combination, maintenance and adjuvant trials
Home Healthcare SettingsRemote monitoring of patients on oral targeted agents

Hospitals lead this dimension with a 55.1% share because open adrenalectomy, steroid replacement and plasma mitotane testing all demand multidisciplinary infrastructure that few other sites can match. Specialty Clinics grow fastest, at an 8.4% CAGR, as kinase inhibitors and maintenance immunotherapy create long outpatient treatment courses that endocrine oncologists can manage outside the hospital. Research and Academic Institutions remain influential because, in a disease this rare, a large share of systemic therapy is delivered inside trials.

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.